We should see most of the secondary endpoints at AHA. Prior to AHA is the ASN Kidney Week conference; late breaking titles should be posted Friday Oct 11. We could have CKD sub study presented there before AHA presentation. Cognition sub-study is on the schedule for December CTAD. We could get top-line news on CKD or cognition sub studies any day. There are other pre-specified subgroup analyses of the primary endpoint too besides atorvastatin vs. rosuvastatin. For example, there could be significant MACE reduction in those with baseline eGFR<60.

See event list here.

See long winded other post here covering lots of stuff.

BDAZ